vs
BillionToOne, Inc.（BLLN）与Fortrea Holdings Inc.（FTRE）财务数据对比。点击上方公司名可切换其他公司
Fortrea Holdings Inc.的季度营收约是BillionToOne, Inc.的7.9倍（$660.5M vs $83.5M）。BillionToOne, Inc.净利率更高（6.8% vs -4.9%，领先11.8%）。BillionToOne, Inc.同比增速更快（117.4% vs -5.2%）。Fortrea Holdings Inc.自由现金流更多（$121.6M vs $6.5M）
BillionToOne, Inc.是一家生命科学与分子诊断企业，专注研发高精度基因检测解决方案，核心产品包括无创产前检测、肿瘤诊断试剂及罕见病筛查服务，服务全球多地的医疗机构、患者及科研合作方。
Fortrea Holdings Inc.是一家总部位于美国北卡罗来纳州达勒姆、注册地为特拉华州的合同研究组织，业务覆盖90个国家，主要服务制药、生物技术和医疗器械行业客户，为相关领域的研发提供专业支持。
BLLN vs FTRE — 直观对比
营收规模更大
FTRE
是对方的7.9倍
$83.5M
营收增速更快
BLLN
高出122.6%
-5.2%
净利率更高
BLLN
高出11.8%
-4.9%
自由现金流更多
FTRE
多$115.1M
$6.5M
损益表 — Q3 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $83.5M | $660.5M |
| 净利润 | $5.7M | $-32.5M |
| 毛利率 | 69.9% | — |
| 营业利润率 | 11.5% | -2.1% |
| 净利率 | 6.8% | -4.9% |
| 营收同比 | 117.4% | -5.2% |
| 净利润同比 | 138.3% | 46.9% |
| 每股收益（稀释后） | $0.10 | $-0.25 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BLLNFTRE
| Q4 25 | — | $660.5M | ||
| Q3 25 | $83.5M | $701.3M | ||
| Q2 25 | — | $710.3M | ||
| Q1 25 | — | $651.3M | ||
| Q4 24 | — | $697.0M | ||
| Q3 24 | $38.4M | $674.9M | ||
| Q2 24 | — | $662.4M | ||
| Q1 24 | — | $662.1M |
净利润BLLNFTRE
| Q4 25 | — | $-32.5M | ||
| Q3 25 | $5.7M | $-15.9M | ||
| Q2 25 | — | $-374.9M | ||
| Q1 25 | — | $-562.9M | ||
| Q4 24 | — | $-61.2M | ||
| Q3 24 | $-14.9M | $-27.9M | ||
| Q2 24 | — | $-138.4M | ||
| Q1 24 | — | $-101.0M |
毛利率BLLNFTRE
| Q4 25 | — | — | ||
| Q3 25 | 69.9% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 52.6% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
营业利润率BLLNFTRE
| Q4 25 | — | -2.1% | ||
| Q3 25 | 11.5% | -1.2% | ||
| Q2 25 | — | -46.5% | ||
| Q1 25 | — | -79.9% | ||
| Q4 24 | — | -8.0% | ||
| Q3 24 | -32.9% | -2.7% | ||
| Q2 24 | — | -7.7% | ||
| Q1 24 | — | -5.6% |
净利率BLLNFTRE
| Q4 25 | — | -4.9% | ||
| Q3 25 | 6.8% | -2.3% | ||
| Q2 25 | — | -52.8% | ||
| Q1 25 | — | -86.4% | ||
| Q4 24 | — | -8.8% | ||
| Q3 24 | -38.8% | -4.1% | ||
| Q2 24 | — | -20.9% | ||
| Q1 24 | — | -15.3% |
每股收益（稀释后）BLLNFTRE
| Q4 25 | — | $-0.25 | ||
| Q3 25 | $0.10 | $-0.17 | ||
| Q2 25 | — | $-4.14 | ||
| Q1 25 | — | $-6.25 | ||
| Q4 24 | — | $-0.68 | ||
| Q3 24 | $-1.47 | $-0.31 | ||
| Q2 24 | — | $-1.55 | ||
| Q1 24 | — | $-1.13 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $195.2M | $174.6M |
| 总债务越低越好 | $55.0M | — |
| 股东权益账面价值 | $-239.5M | $563.5M |
| 总资产 | $327.5M | $2.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BLLNFTRE
| Q4 25 | — | $174.6M | ||
| Q3 25 | $195.2M | $131.3M | ||
| Q2 25 | — | $81.2M | ||
| Q1 25 | — | $101.6M | ||
| Q4 24 | — | $118.5M | ||
| Q3 24 | — | $105.3M | ||
| Q2 24 | — | $126.2M | ||
| Q1 24 | — | $92.8M |
总债务BLLNFTRE
| Q4 25 | — | — | ||
| Q3 25 | $55.0M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益BLLNFTRE
| Q4 25 | — | $563.5M | ||
| Q3 25 | $-239.5M | $580.8M | ||
| Q2 25 | — | $589.2M | ||
| Q1 25 | — | $858.8M | ||
| Q4 24 | — | $1.4B | ||
| Q3 24 | $-242.9M | $1.5B | ||
| Q2 24 | — | $1.5B | ||
| Q1 24 | — | $1.6B |
总资产BLLNFTRE
| Q4 25 | — | $2.7B | ||
| Q3 25 | $327.5M | $2.7B | ||
| Q2 25 | — | $2.8B | ||
| Q1 25 | — | $3.1B | ||
| Q4 24 | — | $3.6B | ||
| Q3 24 | — | $3.7B | ||
| Q2 24 | — | $3.6B | ||
| Q1 24 | — | $4.2B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $13.8M | $129.1M |
| 自由现金流经营现金流 - 资本支出 | $6.5M | $121.6M |
| 自由现金流率自由现金流/营收 | 7.7% | 18.4% |
| 资本支出强度资本支出/营收 | 8.8% | 1.1% |
| 现金转化率经营现金流/净利润 | 2.42× | — |
| 过去12个月自由现金流最近4个季度 | — | $88.3M |
8季度趋势，按日历期对齐
经营现金流BLLNFTRE
| Q4 25 | — | $129.1M | ||
| Q3 25 | $13.8M | $86.8M | ||
| Q2 25 | — | $21.8M | ||
| Q1 25 | — | $-124.2M | ||
| Q4 24 | — | $17.1M | ||
| Q3 24 | — | $-2.4M | ||
| Q2 24 | — | $273.7M | ||
| Q1 24 | — | $-25.6M |
自由现金流BLLNFTRE
| Q4 25 | — | $121.6M | ||
| Q3 25 | $6.5M | $79.5M | ||
| Q2 25 | — | $14.3M | ||
| Q1 25 | — | $-127.1M | ||
| Q4 24 | — | $13.9M | ||
| Q3 24 | — | $-10.6M | ||
| Q2 24 | — | $262.5M | ||
| Q1 24 | — | $-34.9M |
自由现金流率BLLNFTRE
| Q4 25 | — | 18.4% | ||
| Q3 25 | 7.7% | 11.3% | ||
| Q2 25 | — | 2.0% | ||
| Q1 25 | — | -19.5% | ||
| Q4 24 | — | 2.0% | ||
| Q3 24 | — | -1.6% | ||
| Q2 24 | — | 39.6% | ||
| Q1 24 | — | -5.3% |
资本支出强度BLLNFTRE
| Q4 25 | — | 1.1% | ||
| Q3 25 | 8.8% | 1.0% | ||
| Q2 25 | — | 1.1% | ||
| Q1 25 | — | 0.4% | ||
| Q4 24 | — | 0.5% | ||
| Q3 24 | — | 1.2% | ||
| Q2 24 | — | 1.7% | ||
| Q1 24 | — | 1.4% |
现金转化率BLLNFTRE
| Q4 25 | — | — | ||
| Q3 25 | 2.42× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BLLN
| Prenatal | $74.1M | 89% |
| Oncology | $8.7M | 10% |
FTRE
暂无分部数据
